Efficacy and safety evaluation of a lead gene therapy candidate in propionic acidemia (PA) disease mouse models and bioanalytical assay methods development. Period of performance september 25, 2020…
Ended Awarded Last action
- Contract number
- 75N95020F00005
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,274,579
Award facts
- Contract value 63% obligated
-
- $2,274,579.00 Current, with exercised options
- $3,632,884.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $47,846 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $3,213 | |
| Supplemental Agreement for work within scope | $379,767 | |
| Supplemental Agreement for work within scope | $172,216 | |
| Original award | $1,671,537 |
About this award
This federal contract award, valued at $3,632,884.00, was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to the Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract is for the efficacy and safety evaluation of a lead gene therapy candidate in propionic acidemia (PA) disease mouse models, as well as the development of bioanalytical assay methods. The period of performance is from September 25, 2020 to September 24, 2022, with an ultimate completion date of July 15, 2025. The contract is a cost-plus-fixed-fee delivery order, with no set-aside designation. Lovelace Biomedical Research Institute has experience supporting various federal agencies, including the National Institutes of Health (NIH), Department of Defense (DoD), and Department of Health and Human Services (HHS), with a wide range of preclinical research services.
Description
Efficacy and safety evaluation of a lead gene therapy candidate in propionic acidemia (PA) disease mouse models and bioanalytical assay methods development. Period of performance september 25, 2020 - september 24, 2022
Quick answers
Who was awarded contract 75N95020F00005?
75N95020F00005 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 25, 2020.
How much is contract 75N95020F00005 worth?
The government has obligated $2,274,579 on 75N95020F00005. Its potential value, with all options, is $3,632,884.
Which agency awarded contract 75N95020F00005?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95020F00005, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95020F00005 an order under another contract?
Yes. 75N95020F00005 is a delivery order under 75N95019D00012, an indefinite delivery contract.
Was contract 75N95020F00005 competed?
The extent of competition for 75N95020F00005 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award